ARAY:NSD-Accuray Incorporated (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 3.73

Change

0.00 (0.00)%

Market Cap

USD 0.34B

Volume

3.03M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Accuray Incorporated develops, manufactures, and sells radiotherapy systems for alternative cancer treatments in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California. Address: 1310 Chesapeake Terrace, Sunnyvale, CA, United States, 94089

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-18 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology Inc

N/A

USD56.93B 82.00 56.77
PODD Insulet Corporation

N/A

USD20.14B 2,208.27 246.50
ABMD Abiomed Inc

N/A

USD16.11B 104.97 54.72
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

N/A

USD12.59B 53.70 28.22
SWAV ShockWave Medical Inc

N/A

USD7.98B N/A N/A
TNDM Tandem Diabetes Care Inc

N/A

USD7.72B 1,188.64 241.30
IART Integra LifeSciences Holdings ..

N/A

USD5.89B 28.84 19.08
INMD InMode Ltd

N/A

USD5.45B 47.70 37.41
LIVN LivaNova PLC

N/A

USD4.41B 77.40 N/A

ETFs Containing ARAY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.55% 23% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.55% 23% F 26% F
Trailing 12 Months  
Capital Gain 40.75% 50% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.75% 50% F 59% F
Trailing 5 Years  
Capital Gain -33.27% 34% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.27% 34% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain 6.74% 29% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.74% 29% F 40% F
Risk Return Profile  
Volatility (Standard Deviation) 53.18% 62% D- 34% F
Risk Adjusted Return 12.67% 27% F 27% F
Market Capitalization 0.34B 47% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 77.60 36% F 14% F
Price/Book Ratio 4.62 52% F 32% F
Price / Cash Flow Ratio 8.80 24% F 40% F
EV/EBITDA 21.41 63% D 35% F
Management Effectiveness  
Return on Equity -9.53% 72% C- 45% F
Return on Invested Capital 8.27% 86% B 75% C
Return on Assets 2.86% 87% B+ 69% D+
Debt to Equity Ratio 246.96% 9% F 8% F
Technical Ratios  
Short Ratio 16.63 4% F 4% F
Short Percent 10.55% 9% F 16% F
Beta 1.87 20% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector